Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activityReinforce EP4 receptor antagonism as a validated, high-value strategy to overcome ...
TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025 Treatment with TONMYA provided statistically significant pain ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果